| Bioactivity | Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease[1]. |
| Target | SARS-CoV-2. |
| Invitro | Nepuvibart (ZRC3308-B10; 0-5×105 ng/mL) shows virus neutralizing ability in VeroE6/Vero CCL81 (SARS-CoV-2 infection model) cells, when in combination with ZRC3308-A7 (ratio 1:1)[1].Nepuvibart neutralizes SARS-CoV-2 variants B.1.1.7, B.1.351, B.1.617.2, and B.1.617.2AY.1 in vitro, when in combination with ZRC3308-A7 (ratio 1:1) [1].Nepuvibart binds to the RBD of SARS-CoV-2 S1 protein[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | Nepuvibart (ZRC3308-B10; 0.5, 2.5, 25 mg/kg; 48 h prior to the SARS-CoV-2 infection) effectively prevents SARS-CoV-2 infection in syrian hamster, when in combination with ZRC3308-A7 (ratio 1:1)[1].Nepuvibart (0.5, 2.5, 25 mg/kg; i.p.; single) shows the serum levels remaines constant without much reduction for up to 7 days, in syrian hamster [1]. Animal Model: |
| Name | Nepuvibart |
| CAS | 2640224-48-0 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yadav PD, et al. ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection. Viruses. 2021 Dec 3;13(12):2424. |